Treatment Information

Back

Breast Cancer treatment details. Chemotherapy, Biologic therapy.

University of Alberta, Edmonton, Alberta, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:5City/State/Province:Edmonton, Alberta
Treatments:Chemotherapy, Biologic therapyHospital:University of Alberta
Drugs:Journal:Link
Date:Jan 2015

Description:

Patients:
This phase 3 study involved female metastatic breast cancer patients who were divided into two separate treatment groups. Group A had 759 patients with a median age of 54 years, and group B had 385 patients with a median age of 54 years.

Treatment:
Patients in group A received chemotherapy with docetaxel and biologic therapy with ramucirumab (a monoclonal antibody that blocks the VEGFR-2 protein and interferes with cancer cell growth).

Patients in group B received chemotherapy with docetaxel and a placebo.

Toxicities:
This study reported grade 3 or higher fatigue, neutropenia with fever, congestive heart failure, and blood clots. However, treatment-related deaths (grade 5 toxicity) were not specifically mentioned.

Results:
The median overall survival rates for groups A and B were 27.3 and 27.2 months, respectively.

Support:
This study was supported by Eli Lilly/ImClone Systems, makers of ramucirumab.

Correspondence: Dr. John R. Mackey; email: [email protected]



Back